Published in Beilstein J Org Chem on June 10, 2014
Dendritic cells and the control of immunity. Nature (1998) 56.54
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Cancer immunotherapy comes of age. Nature (2011) 12.35
Taking dendritic cells into medicine. Nature (2007) 11.82
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol (2009) 4.98
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
DC-based cancer vaccines. J Clin Invest (2007) 3.81
C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol (2002) 3.44
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Dendritic cells in cancer immunotherapy. Annu Rev Immunol (2000) 2.11
Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol (2002) 2.04
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol Cell Biol (2008) 1.35
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32
Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol (1987) 1.27
Regulatory dendritic cells: there is more than just immune activation. Front Immunol (2012) 1.25
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother (2007) 1.21
Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med (2009) 1.16
Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother (2005) 1.16
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol (2010) 0.97
Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nat Commun (2012) 0.94
Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) (2006) 0.94
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med (2011) 0.88
Synthesis, conformational studies, binding assessment and liposome insertion of a thioether-bridged mimetic of the antigen GM3 ganglioside lactone. Chembiochem (2007) 0.83
Multivalent presentation of a hydrolytically stable GM(3) lactone mimetic as modulator of melanoma cells motility and adhesion. Bioorg Med Chem (2013) 0.80
Density of GM3 with normal primary structure determines mouse melanoma antigenicity; a new concept of tumor antigen. Jpn J Cancer Res (1989) 0.80
Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells. Bioconjug Chem (2010) 0.80
Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother (2008) 0.79
BODIPY-labeled DC-SIGN-targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells. Biomacromolecules (2012) 0.79
Gangliosides in human uveal melanoma metastatic process. Int J Cancer (1996) 0.78
Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone. Jpn J Cancer Res (1990) 0.77